Hepatic impairment No dose adjustment is necessary in sufferers with moderate or reasonable (Boy or girl-Pugh A or B) hepatic impairment (see area five.2). Publicity to midostaurin and its active metabolite CGP62221 is significantly reduce in patients with significant hepatic impairment than that in people with ordinary hepatic purpose (see https://gustavew853nsx6.wiki-racconti.com/user